Photo: JUSTIN TALLIS/AFP via Getty Images AstraZeneca (AZN.L ... the proposed deal will need regulatory sign off before it can go ahead. Pascal Soriot, chief executive of AstraZeneca, said: "Alexion ...

The British company also said Sharon Barr, head of research and development at Alexion, would succeed Mene Pangalos, the long-time biopharmaceuticals head of research at AstraZeneca. Sign up here.

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

read more Sign up here. The British company said on Saturday that Alexion shareholders would receive $60 in cash and about $115 worth of equity per share - either in AstraZeneca's UK-traded ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a $753 million hit for abandoning one of the drugs from that ...

Monopar Therapeutics (NASDAQ:MNPR) rose around 20% ahead of trading on Thursday after it announced an agreement with Alexion, AstraZeneca Rare Disease, the group within AstraZeneca (NASDAQ ...

A little more than a year since its acquisition by AstraZeneca plc, Alexion Pharmaceuticals Inc. is operating in "the best of both worlds" as the official rare disease unit of the U.K. pharma giant.

Voydeya was developed within Alexion, AstraZeneca Rare Disease, the pharma giant’s rare disease division created from the 2021 acquisition of Alexion Pharmaceuticals for $39 billion. As a ...

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 ...

Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in cash and shares to bolster its positions in immunology and rare diseases. AstraZeneca ...